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ABSTRACT
Objective To compare the epidemiological characteristics 
and transmission dynamics in relation to interventions 
against the COVID-19 and severe acute respiratory 
syndrome (SARS) outbreak in mainland China.
Design Comparative study based on a unique data set of 
COVID-19 and SARS.
Setting Outbreak in mainland China.
Participants The final database included 82 858 
confirmed cases of COVID-19 and 5327 cases of SARS.
Methods We brought together all existing data sources 
and integrated them into a comprehensive data set. 
Individual information on age, sex, occupation, residence 
location, date of illness onset, date of diagnosis and 
clinical outcome was extracted. Control measures 
deployed in mainland China were collected. We 
compared the epidemiological and spatial characteristics 
of COVID-19 and SARS. We estimated the effective 
reproduction number to explore differences in transmission 
dynamics and intervention effects.
Results Compared with SARS, COVID-19 affected more 
extensive areas (1668 vs 230 counties) within a shorter 
time (101 vs 193 days) and had higher attack rate (61.8 vs 
4.0 per million persons). The COVID-19 outbreak had only 
one epidemic peak and one epicentre (Hubei Province), 
while the SARS outbreak resulted in two peaks and two 
epicentres (Guangdong Province and Beijing). SARS- 
CoV-2 was more likely to infect older people (median 
age of 52 years), while SARS- CoV tended to infect young 
adults (median age of 34 years). The case fatality rate 
(CFR) of either disease increased with age, but the CFR of 
COVID-19 was significantly lower than that of SARS (5.6% 
vs 6.4%). The trajectory of effective reproduction number 
dynamically changed in relation to interventions, which 
fell below 1 within 2 months for COVID-19 and within 5.5 
months for SARS.
Conclusions China has taken more prompt and effective 
responses to combat COVID-19 by learning lessons from 
SARS, providing us with some epidemiological clues to 
control the ongoing COVID-19 pandemic worldwide.
INTRODUCTION
Severe acute respiratory syndrome (SARS), 
caused by an emerging coronavirus 
(SARS- CoV), initially occurred in Guang-
dong Province in China in November 2002, 
and led to 8437 cases and 813 deaths in 32 
countries and regions.1 After July 2003, the 
SARS outbreak was brought under control, 
thanks to the world’s enormous efforts. A total 
of 5327 cases with 343 deaths were reported 
in mainland China.2 Seventeen years later, 
another emerging coronavirus, SARS- CoV- 2, 
was identified in Wuhan in Hubei Province 
in China in December 2019,3 and resulted 
in a worldwide COVID-19 pandemic .4 As of 
28 April, a total of 213 countries or territo-
ries have been affected, with more than 2.95 
million cases reported and over 202 000 
deaths.5 The whole world is facing a health 
crisis, which is greatly challenging the public 
health system.6 The specific characteristics 
of COVID-19 in comparison with SARS and 
whether the COVID-19 pandemic can be 
controlled by the same measures done during 
the SARS outbreak are of great interest now.7 
Strengths and limitations of this study
 ► We brought together all existing Chinese data sourc-
es for COVID-19 and severe acute respiratory syn-
drome (SARS) and integrated them into one unique 
data set.
 ► We comprehensively assessed the epidemiological 
characteristics and transmission dynamics of the 
COVID-19 and SARS outbreak in mainland China to 
provide clues to control the ongoing COVID-19 pan-
demic worldwide.
 ► All cases of SARS show symptoms, while this is not 
the case for COVID-19; therefore, more serological 
evidence are needed to compare the epidemiolog-
ical characteristics of the two diseases.
 ► The denominator for the case fatality rate of 
COVID-19 might be biased towards confirmed cas-
es and more severe disease, and the true mortality 
might be overestimated.
 ► We only compared the most important events and 
public health control measures in the estimation of 
Rt out of dozens of control measures implemented in 
mainland China.
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After nearly 3 months of strong political commitment 
and centrally coordinated response, mainland China 
had only sporadic locally transmitted and a few imported 
COVID-19 cases at the time of writing, and all cases had 
been discharged from the hospital in the epicentre 
Wuhan.8
During the SARS outbreak in 2002–2003, no functional 
infectious diseases surveillance system was available in 
mainland China and the reporting system was outdated, 
which hampered data collection and delayed inter-
ventions.9 After the outbreak, we brought together all 
existing Chinese data sources and integrated them into 
one comprehensive data set.2 10 In the current study, we 
compare the epidemiological characteristics and trans-
mission dynamics in relation to public health control 
measures against the COVID-19 and SARS outbreak in 
mainland China using a unique SARS data set as well 
as the national surveillance database of COVID-19, to 
provide experience in effectively fighting the ongoing 
COVID-19 pandemic.
METHODS
Data collection and database construction
We collected data on COVID-19 from the China Informa-
tion System for Diseases Control and Prevention and offi-
cial reports by national, provincial and municipal health 
commissions. Individual information on age, sex, occu-
pation, residence location, date of illness onset, date of 
diagnosis and clinical outcome was extracted. The final 
database included 82 858 confirmed cases of COVID-19 
(all showing clinical manifestations) with 4633 deaths in 
mainland China from 8 December 2019 to 28 April 2020. 
Information on public health measures was obtained 
from the website of the National Health Commission 
(NHC) of the People’s Republic of China (http://www. 
nhc. gov. cn/).
We integrated data on reported SARS cases in mainland 
China derived from all available data sources at various 
levels.2 The databases comprised demographic charac-
teristics, residence location, date of illness onset, date of 
diagnosis and clinical outcome of cases. After integrating 
data from different sources, we removed duplicate cases 
and filled in missing data by comparing the medical 
records of cases with individual case records of different 
data sources. The final database included 5327 SARS cases 
with 343 deaths in mainland China from 16 November 
2002 to 28 May 2003. Information on control measures 
was obtained from the website of WHO (https://www. 
who. int/ csr/ don/ archive/ disease/ severe_ acute_ respira-
tory_ syndrome/ en/).
Statistical analyses
Normally distributed data were expressed as mean±SD, 
while skewed data were described as median (IQR). Cate-
gorical variables were reported as frequency (n) and 
proportion (%). To estimate differences between groups, 
Student’s t- test or Wilcoxon rank- sum test for continuous 
variables and χ2 test or Fisher’s exact test for categorical 
variables were used, where appropriate.
Attack rate (AR) was calculated to characterise the 
epidemic magnitude and dimensions of COVID-19 and 
SARS in mainland China. AR with 95% CI was computed 
using the population estimate of the national census in 
2010 obtained from the National Bureau of Statistics of 
China and presented as the number of cases per million 
persons. Thematic maps on the AR of COVID-19 and 
SARS at county level were created using ArcGIS V.10.2 
software (ESRI, Redlands, California, USA). Case fatality 
rate (CFR) was defined as the proportion of deaths 
among identified confirmed cases. We compared the CFR 
between male and female patients, for different age cate-
gories, and estimated the OR and 95% CI by maximum 
likelihood method. Multivariate logistic regression anal-
ysis was conducted to validate male and female differ-
ences in CFR after adjusting for age, occupation and 
onset- to- diagnosis interval. All analyses were conducted 
using SPSS V.21.0 and R V.3.6.3 software. A two- sided p 
value less than 0.05 was considered statistically significant.
We estimated the effective reproduction number on 
day t (Rt) separately for COVID-19 and SARS to explore 
differences in transmission dynamics and intervention 
effects. Rt is defined as the mean number of secondary 
cases generated by one primary case with illness onset on 
day t using the method developed by Cori et al (online 
supplementary text 1).11 The CI of Rt was quantified using 
a bootstrap procedure.12
Patient and public involvement
Patients and the public were not involved in the design or 
conduct of the study.
RESULTS
As shown in table 1, the COVID-19 outbreak began on 
8 December 2019 and is still ongoing. A total of 82 858 
cases had been diagnosed by 28 April 2020, resulting in 
an overall AR of 61.8 (95% CI 61.4 to 62.2) per million 
persons. Of these cases 4633 have died, resulting in a CFR 
of 5.6% (95% CI 5.4 to 5.8). The SARS outbreak started in 
mainland China on 16 November 2002 and lasted for 193 
days, until 28 May 2003. A total of 5327 cases were diag-
nosed, with an AR of 4.0 (95% CI 3.9 to 4.1) per million 
persons, which was much lower than that of COVID-19 
(p<0.0001). Among them 343 cases died, resulting in a 
CFR of 6.4% (95% CI 5.8 to 7.1), which was significantly 
higher than COVID-19 (p=0.01). The median age of 
COVID-19 cases was 52 years (IQR 39–63), which was 
significantly older than that of SARS cases (34 years; 
IQR 24–47) (p<0.0001). The male to female ratio was 
not significantly different between COVID-19 and SARS 
(p=0.08). The proportion of healthcare workers among 
COVID-19 cases was 4.1% (95% CI 4.0 to 4.2), which was 
significantly lower than among SARS cases (19.2%; 95% CI 
18.7 to 19.7) (p<0.0001). The average interval from onset 
of illness to diagnosis among COVID-19 cases decreased 
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dramatically at different stages during the course of the 
outbreak, while the intervals among SARS cases were basi-
cally stable (online supplemental figure 1). The overall 
median onset- to- diagnosis interval of COVID-19 was 8 
days (IQR 4–13), which was significantly longer than that 
of SARS (median 5 days; IQR 2–9) (p<0.0001).
Figure 1 shows the geographical distribution of 
COVID-19 and SARS in mainland China. The adminis-
trative divisions including provinces, autonomous regions 
and municipalities of mainland China were all referred to 
as provinces for simplicity. COVID-19 affected 1668 coun-
ties in all 31 provinces, with Hubei Province as the only 
epicentre. ARs of all districts and counties in Wuhan, the 
capital city of Hubei Province, were higher than 1200.0 
per million persons, ranging from 1253.6 (Xinzhou 
District) to 9750.4 (Hannan District). Generally speaking, 
the shorter the distance of an area from Wuhan, the 
higher its AR. Counties with an AR over 500.0 per million 
persons were mainly located in the surrounding areas of 
Wuhan (figure 1A). SARS cases were identified in 230 
counties of 23 provinces, and clustered in Guangdong 
Province and the surrounding areas of Beijing. The ARs 
were over 100.0 per million persons in about half of the 
affected districts and counties of Guangzhou and Beijing. 
Most affected counties in other areas had ARs lower than 
10.0 per million persons (figure 1B).
The COVID-19 outbreak lasted for 142 days so far with 
only one peak (figure 2A). From 8 December 2019 to 
19 January 2020, COVID-19 mainly occurred in Wuhan. 
Thereafter, the number of COVID-19 cases grew rapidly 
and peaked around 26 January 2020. After the Chinese 
authorities adopted vigorous and extensive control 
measures on 23 January 2020, the outbreak showed a 
markedly decreasing trend. Since mid- March, most cases 
were imported or import- related. In contrast, the SARS 
outbreak lasted for 193 days with two peaks (figure 2B). 
The first wave was characterised by local transmission in 
Guangdong Province from 16 November 2002 to early 
March 2003, and peaked around 8 February. The second 
wave was caused by the spread of SARS to other provinces, 
which lasted from early March to 28 May 2003, with the 
peak around 26 April 2003. The Beijing metropolis was 
the second epicentre after Guangdong Province.
SARS- CoV-2 tended to infect people 50 years or older, 
accounting for 55.6% cases, and the AR of COVID-19 
increased with age. On the contrary, SARS- CoV was 
more likely to infect young adults between 20 and 49 
years, accounting for 69.9% cases, and the AR dramat-
ically decreased with age (figure 3A). The overall AR 
of COVID-19 in women (61.6 per million persons) 
was significantly higher than in men (58.3 per million 
persons; p<0.0001), while male and female differences in 
AR were not found in SARS cases (p=0.86). The CFR for 
both COVID-19 and SARS increased strongly with age (χ2 
test of linear trend, both p<0.0001) and was significantly 
higher among male cases in comparison with female 
cases, with an OR of 1.8 (95% CI 1.7 to 2.0; p<0.0001) for 
COVID-19 and 1.4 (95% CI 1.1 to 1.8; p=0.003) for SARS 
(figure 3B). Multivariate regression analysis revealed that 
the male and female difference in CFR remained signifi-
cant for both diseases after adjusting for age, occupation 
and onset- to- diagnosis interval. The adjusted OR was 1.9 
(95% CI 1.8 to 2.0; p<0.0001) for COVID-19 and 1.3 (95% 
CI 1.0 to 1.7; p=0.043) for SARS.
We further evaluated the transmission dynamics of 
both COVID-19 and SARS outbreak by estimating trends 
in Rt in relation to public health interventions. Although 
various actions had been implemented in mainland China 
during the outbreak (online supplemental table 1), we 
selected seven important events and control measures, 
and displayed the duration from disease emergence to 
initiation of each action as the background of Rt curves. 
As shown in figure 4A, Rt fluctuated greatly between 1.5 
and 3.0 at the beginning of the COVID-19 outbreak. 
On 31 December 2019, the Wuhan Health Committee 
announced the outbreak publicly. Three days later, NHC 
notified WHO of the emerging infectious disease, when 
Rt was up to 2.5. About 1 week after the disease was first 
notified, the novel coronavirus was isolated and identified 
as the causative agent. On 11 January 2020, diagnostic kits 
were available and provided to Wuhan. Regular control 
measures, such as case finding and contact tracing, were 
Table 1 Main epidemiological characteristics of COVID-19 and SARS in mainland China
Characteristics COVID-19* SARS P value
Time of the epidemic 8 December 2019– 16 November 2002–28 May 2003 NA
Number of cases 82 858 5327 NA
Attack rate (per million persons) 61.8 (95% CI 61.4 to 62.2) 4.0 (95% CI 3.9 to 4.1) <0.0001
CFR (%) 5.6 (95% CI 5.4 to 5.8) 6.4 (95% CI 5.8 to 7.1) 0.01
Age (years), median (IQR) 52 (39–63) 34 (24–47) <0.0001
Sex, male to female ratio 1.0 (39 777/40 067)† 1.0 (2720/2607) 0.08
Healthcare workers, n (%) 3402 (4.1) (95% CI 4.0 to 4.2) 1021 (19.2) (95% CI 18.7 to 19.7) <0.0001
Onset- to- diagnosis interval (days), median (IQR) 8 (4–13) 5 (2–9) <0.0001
*Data on COVID-19 were collected up to 28 April 2020.
†Number of COVID-19 cases with sex records.
CFR, case fatality rate; NA, not applicable; SARS, severe acute respiratory syndrome.
4300.7802.430. P
rotected by copyright.
 on N
ovem
ber 26, 2020 at E
rasm
us M
edical / X
51
http://bm
jopen.bm
j.com
/
B
M
J O
pen: first published as 10.1136/bm
jopen-2020-043411 on 15 O
ctober 2020. D
ow
nloaded from
 
4 Zhao L, et al. BMJ Open 2020;10:e043411. doi:10.1136/bmjopen-2020-043411
Open access 
taken.13 Rt subsequently decreased to 1.7. However, due 
to the spread to and within other parts of China besides 
Wuhan, Rt steadily increased. Chinese authorities then 
started to take very vigorous intervention measures, such 
as mandatory reporting, lockdown of Wuhan, extending 
the Spring Festival holidays and postponing the school 
semester. Immediately, Rt consistently decreased to below 
1 in the following 2 weeks. On 4 February, Huoshen-
shan Hospital was put into operation and Rt consistently 
decreased to nearly 0 on 20 March. After this, Rt increased 
again and fluctuated around 1 due to the emergence of 
sporadic locally transmitted cases.
As shown in figure 4B, Rt of SARS fluctuated significantly 
from the beginning to early February 2003, with a wide 
CI. When China notified WHO about the unknown pneu-
monia on 10 February (86 days after the first case of SARS 
emerged) and officially reported the outbreak 1 day later, 
regular control measures were conducted in Guangdong 
Figure 1 Comparison of attack rates between COVID-19 and severe acute respiratory syndrome (SARS) in mainland China. 
(A) Attack rates of COVID-19 in affected counties as of 28 April 2020. (B) Attack rates of SARS in affected counties from 16 
November 2020 to 28 May 2003. The cities mainly reporting cases at the city level are highlighted with purple edging.
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Province and Rt dropped to below 1 within 1 week. Due to 
the transmission in Beijing and neighbouring provinces, 
Rt reincreased to above 1. On 13 April, SARS was listed as 
a notifiable infectious disease and reported mandatorily; 
however, Rt did not show a decreasing trend. It was only 
from 19 April to 26 April that Chinese authorities gained 
full control of all activities to combat SARS (154 days 
after the outbreak). Within 1 week, Rt fell to around 1. 
On 30 April, Xiaotangshan Hospital was open, and diag-
nostic kits were available 1 day later. Rt remained stable 
and never exceeded 1 again. The durations from the 
emergence of COVID-19 to official announcement, noti-
fication of WHO, identification of aetiology, availability 
of diagnostics, mandatory reporting, full governmental 
control and specialised hospitals were all remarkably 
shorter in comparison with SARS.
DISCUSSION
By 26 April 2020, all hospitalised patients with COVID-19 
in Wuhan, the epicentre, where the virus was first detected 
last December 2019, had been discharged,14 indicating 
that the first wave of COVID-19 outbreak in mainland 
China was coming to an end. This paper describes the 
differences between the COVID-19 and SARS outbreak in 
mainland China with respect to epidemiological charac-
teristics and transmission dynamics.
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Figure 2 Epidemic curves of COVID-19 and severe acute respiratory syndrome (SARS) in mainland China. (A) Epidemic curve 
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The COVID-19 outbreak has spread more extensively 
in mainland China and affected 1668 counties in all 31 
provinces, which is over seven times more than that of 
the SARS outbreak. Wuhan, the capital city of Hubei 
Province, was the only epicentre whilst the surrounding 
counties had much higher ARs. The COVID-19 outbreak 
coincided with the Spring Festival holidays, when people 
traditionally go home to celebrate Chinese New Year. The 
large- scale population movement and convenient trans-
portation have undoubtedly accelerated the transmis-
sions especially during the early stage of the outbreak.15–17 
Learning from experience and lessons from the SARS 
outbreak,18 19 very strict public health measures had been 
taken to combat the COVID-19 outbreak since 23 January 
2020. It turned out to be effective in controlling the spread 
of COVID-19 from Hubei Province to other provinces, 
probably preventing a second epicentre in mainland 
China. Although the SARS outbreak has affected much 
fewer (230) counties with much lower ARs, it did result 
in a secondary epicentre in Beijing and its surrounding 
areas.
COVID-19 has spread more rapidly and took only 44 
days to spread from Hubei to all other provinces across 
mainland China. Although COVID-19 emerged in 
Wuhan, its epidemic peaks in either Wuhan or Hubei as 
well as in other provinces occurred at nearly the same time 
on 24–28 January 2020. As the clinically diagnosed cases 
were included in the updated version of case definition, 
an abnormal peak value of daily new cases was recorded 
on 1 February. The epidemic curve might reflect the great 
effects of all control measures coordinated by the central 
government. The strict public health measures such as 
the complete lockdown of cities, active case surveillance, 
quarantine of contacts and the compulsory use of masks 
in the general population are probably extreme but have 
helped achieve good results. These experiences can 
be taken into consideration by other countries in their 
response to COVID-19.20 Taking a look back at the SARS 
Figure 3 Comparison of age and sex differences between COVID-19 and severe acute respiratory syndrome (SARS) in 
mainland China. (A) Attack rate of COVID-19 (left) and SARS (right) in different age and sex groups. (B) Case fatality rate of 
COVID-19 (left) and SARS (right) in different age and sex groups.
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outbreak, the peak of the first wave occurred in the initial 
epicentre of Guangdong Province in late January and 
mid- February 2003. Thereafter the epidemic gradually 
subsided. Unfortunately, this reduction did not continue 
and was followed with further national spread and led 
to the second peak around late April 2003. When the 
Chinese government initiated impressive nationwide 
control measures, the SARS outbreak was contained 
within 2 months.21 The trade- off between social economic 
consequences and timely health effects might be an 
important lesson that China and other countries around 
the world can learn from the SARS outbreak.
There are obvious differences in age distribution 
between COVID-19 and SARS. Most COVID-19 cases were 
people 50 years or older, with a median age of 52 years. 
Meanwhile, both AR and CFR increased with age. On 
the contrary, most SARS cases were young adults, with a 
median age of 34 years. The AR tended to decrease with 
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age, but the CFR increased with age, except for the 0–19 
years age group. The results of analysis on sex differences 
in COVID-19 are controversial. Our study shows that AR 
is higher among women than men, which is consistent 
with reports in South Korea and Germany.22 23 Other 
studies, however, came with an opposite conclusion that 
COVID-19 is more prevalent among men24 25 or that the 
diagnosis rates are similar between sexes.26 Different 
population composition, case definitions and inclusion 
criteria, and gender- associated risk of exposure might lead 
to the discrepancy between studies. CFRs are greater in 
men than in women in mainland China, indicating a sex 
predisposition to COVID-19. The same findings have been 
reported in most countries,26 27 with men more prone to 
severe COVID-19 and death. A similar trend in sex bias in 
mortality was also observed in the prior SARS epidemic.26 
Sex- specific disease outcomes might be attributed to the 
sex- dependent production of steroid hormones and the 
different copy numbers of immune response X linked 
genes in men and women.28 Additionally, social factors 
including smoking and healthcare- seeking behaviours 
as well as sex- related chronic comorbidities might also 
impact disease outcomes.29 30 Although the underlying 
mechanisms require further investigation, our find-
ings imply that greater efforts in effectively preventing 
COVID-19 should be done in older populations and 
more attention should be paid to treatment of older male 
patients in order to reduce mortality.
In the present study, we used CFR to estimate the 
mortality from two diseases. During the early stage of the 
COVID-19 pandemic, a proportion of people with milder 
or no symptoms might have been undetected.31 Addition-
ally, asymptomatic cases were not defined as confirmed 
cases according to the case definition in mainland 
China32 and were not included in the denominator when 
calculating. Therefore, the observed CFR of COVID-19 
tended to be high. In addition, the high value might also 
be skewed by the lethality of the disease in Wuhan (CFR 
of 7.7%), where the outbreak unexpectedly started, with 
over 60.7% of confirmed cases having been recorded in 
mainland China. However, our estimate calculated from 
the COVID-19 data set as of 28 April 2020 was more accu-
rate than previous studies in mainland China,33 where 
the final outcomes remained unknown in some cases.34 
The estimated CFR of SARS in mainland China was much 
lower than other affected countries or regions,2 35 which 
might be due to the relatively young age of SARS cases, 
over- reporting in Guangdong early in the epidemic, and 
the use of rational management and more intense treat-
ment.2 36 37
The dynamic changes in Rt during the COVID-19 and 
SARS outbreak showed clear differences in the timing and 
impact of important actions taken in mainland China. 
Looking retrospectively, due to the imperfect national 
emergency response and insufficient attention to the 
emerging infectious diseases during the SARS epidemic, 
national control measures were delayed. However, the late 
interventions still contributed much to speeding up the 
elimination of SARS, given the fact that the epidemic was 
fully controlled after the central government took lead-
ership.10 Since 2003, China has improved its epidemic 
response capacity, which played a key role in fighting 
COVID-19. After an obvious fluctuation at the very begin-
ning of COVID-19, Rt was maintained at a low level for 
about a week in mainland China before 31 December 
2019. Unfortunately, China missed the best opportunity 
to end the outbreak early, as COVID-19 was only identi-
fied as a zoonosis, with the important clue being an expo-
sure history to the Huanan Seafood Wholesale Market.38 
Regular control measures such as case finding, contact 
tracing and investigations of infective sources imple-
mented in the epicentre were shown to be effective and 
decreased Rt to about 2.0. However, since 10 January 2020, 
Rt steadily increased again due to COVID-19 occurrence 
in many parts outside of Wuhan. After person- to- person 
transmission was confirmed, the most stringent control 
measures have been taken since 23 January. The set of 
control measures was certainly necessary, adequate and 
effective, given the fact that Rt dropped to below 1 in just 
a period of 2 weeks.
These facts implied that non- pharmaceutical control 
measures deployed in mainland China can actually halt the 
epidemics of diseases, even in 2003 when the government 
had a slow response to SARS. The remarkable success was 
mainly due to the vigorous old- style public health control 
measures implemented, especially isolation and quaran-
tine, social distancing and community containment.39 
Compared with Western countries, Chinese authorities 
took isolation of all cases more seriously, including mild 
cases, during the COVID-19 epidemic, and developed the 
Fangcang shelter hospitals to particularly isolate and treat 
patients with mild to moderate COVID-19.40 Compared 
with isolating at home, this institutional- based isolation 
substantially decreased the risk of transmission between 
families and communities.41 The wide use of big data, 
sophisticated artificial intelligence and machine learning 
algorithms is crucial to retracing the movement of 
infected persons and tracing close contacts.42 In addition, 
mainland China is preventing importation and onward 
transmission strictly through custom inspection and 
border quarantine.43 Every incoming traveller (including 
returning residents) is subject to a nucleic acid testing 
and a 14- day mandatory quarantine at a designated 
central facility in the city of first entry point.44 Clearly the 
Chinese government has acted more quickly and effec-
tively this time. The strong political commitment, the 
centrally coordinated response and mass participation 
across the whole country have played a very important 
role in containing COVID-19 in mainland China. These 
efforts represent welcome progress and development for 
global health security and diplomacy.45
There are some limitations to this study. First, all cases 
of SARS are symptomatic, while a proportion of cases 
infected with COVID-19 had mild or no symptoms and 
passed unnoticed. Comparative results between the two 
diseases should be interpreted with caution and more 
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evidence- based serological data are needed. Second, our 
estimates of fatality rate were based on confirmed cases 
detected through national surveillance and calculated 
using crude methods. The denominator for the CFR of 
COVID-19 might be biased towards confirmed cases and 
more severe disease, and the true mortality might thus 
be overestimated. These biases are difficult to overcome 
early in a pandemic. Therefore, future studies estimating 
the ratio of deaths among all infected individuals will 
be needed to measure mortality more accurately. Third, 
although dozens of local and national, small- scale or large- 
scale control measures were implemented in different 
areas, we only compared the most important events and 
control measures in the estimation of Rt.
In conclusion, the ongoing COVID-19 outbreak spread 
more quickly to more extensive areas within a shorter 
period of time, in comparison with the SARS outbreak 
in 2002–2003, which implies higher transmissibility of 
SARS- CoV-2. However, COVID-19 only had one epicentre 
with one peak, unlike SARS with two epicentres and 
two epidemic peaks, which indicates early response and 
prevention measures were effective. The age and sex 
distributions between COVID-19 and SARS are different 
in terms of AR, but crudely the same in fatality rate. The 
comparison of Rt in relation to response activities reveals 
that the durations from the emergence of COVID-19 to 
official announcement, notifying WHO, identification of 
aetiology, availability of diagnostics, mandatory reporting 
and centrally coordinated response were remarkably 
shorter in comparison with SARS, indicating a more 
prompt and effective response. These findings provide 
helpful information that can be used to fight the ongoing 
COVID-19 pandemic worldwide.
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